SPRC Stock Overview
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SciSparc Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.29 |
| 52 Week High | US$23.66 |
| 52 Week Low | US$1.27 |
| Beta | 1.26 |
| 1 Month Change | -40.55% |
| 3 Month Change | -61.26% |
| 1 Year Change | -91.30% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.90% |
Recent News & Updates
Shareholder Returns
| SPRC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -27.7% | -2.2% | -3.7% |
| 1Y | -91.3% | 11.6% | 20.5% |
Return vs Industry: SPRC underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: SPRC underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| SPRC volatility | |
|---|---|
| SPRC Average Weekly Movement | 26.2% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SPRC's share price has been volatile over the past 3 months.
Volatility Over Time: SPRC's weekly volatility has decreased from 31% to 26% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 3 | Oz Adler | scisparc.com |
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form.
SciSparc Ltd. Fundamentals Summary
| SPRC fundamental statistics | |
|---|---|
| Market cap | US$3.49m |
| Earnings (TTM) | -US$5.12m |
| Revenue (TTM) | US$2.88m |
1.2x
P/S Ratio-0.7x
P/E RatioIs SPRC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRC income statement (TTM) | |
|---|---|
| Revenue | US$2.88m |
| Cost of Revenue | US$683.00k |
| Gross Profit | US$2.20m |
| Other Expenses | US$7.32m |
| Earnings | -US$5.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.89 |
| Gross Margin | 76.28% |
| Net Profit Margin | -177.91% |
| Debt/Equity Ratio | 0% |
How did SPRC perform over the long term?
See historical performance and comparison